Clinical trials: Cardiac Allograft Vasculopathy
Disorder Related to Cardiac Transplantation
Heart Transplant Registry of Városmajor
The purpose of this registry is to determine the long term outcomes of heart transplantations performed at the Semmelweis University Heart and Vascular Center.
- Trial name
- NCT02347371
- Where
- Hungary
- Volunteers
- 11 people
- Sponsor
- Semmelweis University Heart and Vascular Center
Heart-lung Transplant Rejection
Assessment of Revascularization Versus Conservative Treatment in Heart Transplant Patients for a Clinical Event Reduction
The aim of the study is to compare optimal medical therapy alone versus percutaneous coronary intervention on top of medical therapy in the setting of heart transplant recipient coronary artery disease in a randomized trial.The…
- Trial name
- ARCHER (NCT01795729)
- Testing
- Stent, optimal medical therapy
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cardiac Allograft Vasculopathy
Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Recipients
The main goal of this study is to evaluate the effect of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab on cardiac allograft vasculopathy in de novo heart transplant recipients.
- Trial name
- EVOLVD (NCT03734211)
- Testing
- Evolocumab
- Where
- 5 sites in Denmark, Finland and 1 more
- Volunteers
- 130 people
- Sponsor
- Lars Gullestad
Cardiac Allograft Vasculopathy
Noninvasive Predictors of Transplant Vasculopathy
Post transplant vasculopathy is a major negative outcome in heart transplantation. Current methods of detection are highly invasive and pose a risk to transplant recipients.
- Trial name
- CAV (NCT01424917)
- Where
- United States
- Sponsor
- University of Minnesota
Pediatric Heart Transplantation, Immunosuppression
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
The TEAMMATE Trial will enroll 210 pediatric heart transplant patients from 25 centers at 6 months post-transplant and follow each patient for 2.5 years.
- Conditions
- Pediatric Heart Transplantation, Immunosuppression, Chronic Kidney Diseases, Cardiac Allograft Vasculopathy
- Trial name
- TEAMMATE (NCT03386539)
- Testing
- Everolimus, Tacrolimus, Mycophenolate Mofetil
- Where
- 25 sites in United States
- Volunteers
- 211 people
- Sponsor
- Boston Children's Hospital
Psychiatric Diagnosis, Cognition Disorders
Mood and Cognitive Outcome After Heart Transplantation (the MOODHEART Study)
The investigators aim at characterizing neuropsychiatric consequences of heart transplantation (HTX) and at assessing the impact of depressive symptoms after HTX on mortality and cardiac allograft vasculopathy (CAV).
- Trial name
- NCT02035865
- Where
- Norway
- Volunteers
- 74 people
- Sponsor
- Oslo University Hospital
Heart Transplantation
Advanced Cardiac Imaging in Cardiac Allograft Vasculopathy
Cardiac allograft vasculopathy (CAV) is a process of both immune and non-immune mediated thickening of the heart arteries of transplanted hearts.
- Trial name
- NCT01927614
- Testing
- Cardiac CT
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- Nova Scotia Health Authority
Cardiac Allograft Vasculopathy
Noninvasive Evaluation of Cardiac Allograft Vasculopathy
Abnormal peripheral endothelial function and alterations in circulating biomarkers that are associated with endothelial activation and inflammation correlate with angiographic evidence of cardiac allograft vasculopathy, defined…
- Trial name
- CAVII (NCT01305382)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Minnesota
Cardiac Allograft Vasculopathy
Optical Coherence Tomography (OCT) to Evaluate Cardiac Allograft Vasculopathy (CAV) in Patient's Post Heart Transplant
Cardiac allograft vasculopathy (CAV) is a unique form of accelerated plaque formation seen in the coronary arteries of patients who have received heart transplantation.
- Trial name
- OCTCAV (NCT01403142)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Columbia University
Graft Rejection
Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy
Everolimus is an immunosuppressive drug that is being studied for preventing acute rejection that can happen after heart transplantation. It is usually used in combination with other immunosuppressive drugs such as cyclosporine.
- Trial name
- NCT00097968
- Testing
- everolimus
- Where
- 6 sites in United States
- Sponsor
- Novartis Pharmaceuticals
Intimal Proliferation, Immunosuppression
Intracoronary Analysis of Cardiac Allograft Vasculopathy by Means of Optical Coherence Tomography
Randomized prospective multi-center imaging study which investigates the impact of different immunosuppressive protocols (Everolimus (Certican®) or Mycophenolate mofetil (CellCept®)) on cardiac allograft vasculopathy (CAV) in…
- Trial name
- OCTandCAV (NCT02254668)
- Testing
- Protocol with Everolimus (Certican®), Protocol with Mycophenolate mofetil (CellCept®)
- Where
- Switzerland
- Volunteers
- 278 people
- Sponsor
- University of Zurich
Cardiac Allograft Vasculopathy
Microvascular Cardiac Allograft Vasculopathy Trial
The aim of the mCAV study is a comprehensive characterization of the genetic, morphological and functional phenotype of isolated microvascular graft vasculopathy (mCAV) after orthotopic heart transplantation (OHT).
- Trial name
- mCAV (NCT05826444)
- Testing
- Echocardiography, Magnetic resonance imaging, Magnetocardiography
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- German Heart Institute
Heart Transplantation, Allograft Arteriopathy
Trajectories of Cardiac Allograft Vasculopathy After Heart Transplantation
This project aims: i) to identify Cardiac Allograft Vasculopathy (CAV) trajectories after heat transplantation using latent class mixed modeling, ii) to characterize the global and specific determinants of different trajectories…
- Trial name
- TRAJ-CAV (NCT04117152)
- Testing
- Latent class mixed modeling
- Where
- 3 sites in United States, Belgium and 1 more
- Volunteers
- 1,300 people
- Sponsor
- Paris Translational Research Center for Organ Transplantation
Cardiac Allograft Vasculopathy, Endothelial Dysfunction
Determining the Association of Microvascular Disease as Assessed by PET and Graft Injury by Donor Derived Cell Free DNA
The goal of this research study is to understand if a blood test in people who have had heart transplants can detect and predict the following: Blockages in the small blood vessels of the heart.
- Conditions
- Cardiac Allograft Vasculopathy, Endothelial Dysfunction, Microvascular Coronary Artery Disease
- Trial name
- DEPICT (NCT05756088)
- Testing
- Blood draw to measure the levels of dd-cf DNA
- Where
- United States
- Sponsor
- Yale University
Transplant; Failure, Heart
Impact of Level and Quality of Immunosuppression on Onset and Pattern of Cardiac Allograft Vasculopathy Evaluated by OCT
The aim of this study is to use the high resolution of optical coherence tomography to assess the prevalence of different types of cardiac allograft vasculopathy (CAV) in cardiac transplanted patients and correlate those results…
- Trial name
- IMPROVE-OCT (NCT03079791)
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- LMU Klinikum
Heart Transplantation, Cardiac Allograft Vasculopathy
Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy
Cardiac allograft vasculopathy (CAV) is the major cause of long-term graft failure in heart transplant recipients. Although several immune-mediated and metabolic risk factors have been implicated in the pathogenesis of CAV, no…
- Conditions
- Heart Transplantation, Cardiac Allograft Vasculopathy, Cytomegalovirus Infection
- Trial name
- PROTECT (NCT00966836)
- Testing
- Pre-emptive strategy with valganciclovir plus everolimus, Prophylaxis with valganciclovir plus mycophenolate, Prophylaxis with valganciclovir plus everolimus
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- University of Bologna
Cardiac Transplant Disorder, Cardiac Death
HEart trAnsplantation Registry of piTie-Salpetriere University Hospital
Heart transplantation (HTx) is a procedure which is hindered by several complications. The HEARTS registry aims to allow the analysis of risk factors of all post-HTx complications.
- Conditions
- Cardiac Transplant Disorder, Cardiac Death, Heart Failure, Acute Cellular Graft Rejection
- Trial name
- HEARTS (NCT03393793)
- Volunteers
- 566 people
- Sponsor
- Lee S Nguyen
Vasculopathy, Heart Transplant Failure
The Role of CD34 + Stem Cells and Biomarkers in the Development of CAV in HTX Patients
Coronary allograft vasculopathy represents one of the major limiting factors of long-term survival in heart transplant recipients.
- Trial name
- NCT05485467
- Testing
- coronary CT angiography
- Where
- Slovenia
- Volunteers
- 55 people
- Sponsor
- University Medical Centre Ljubljana
Coronary Artery Disease
Real-World Outcomes of Drug-Coated Balloon Angioplasty in Coronary Artery Disease
The Real-World Drug-Coated Balloon Registry (RW-DCB) is an investigator-initiated, multicenter, observational cohort study evaluating the use of drug-coated balloons (DCBs) during percutaneous coronary intervention (PCI) in…
- Trial name
- RW-DCB (NCT07875088)
- Testing
- Coronary Drug-Coated Balloon
- Where
- 5 sites in Mexico, Spain
- Volunteers
- 2,000 people
- Sponsor
- Kristian Rivera
Cardiac Allograft Vasculopathy
Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy
Cardiac transplantation is the ultimate treatment option for patients with end stage heart failure. Cardiac allograft vasculopathy remains a leading cause of morbidity and mortality after transplantation.
- Trial name
- NCT01078363
- Testing
- ramipril
- Where
- 2 sites in United States
- Volunteers
- 96 people
- Sponsor
- Stanford University